Modelling population-level impact to inform target product profiles for childhood malaria vaccines.

ABSTRACT:

Background

The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5-17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher efficacy for a different schedule demonstrated in a phase 2a challenge study. The objective of our study was to investigate the population-level impact of a modified RTS,S/AS01 schedule and dose amount in order to inform the target product profile for a second-generation malaria vaccine.

Methods

We used a mathematical modelling approach as the basis for our study. We simulated the changing anti-circumsporozoite antibody titre following vaccination and related the titre to vaccine effi

SUBMITTER: Hogan AB 

PROVIDER: S-EPMC6044028 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature